133 related articles for article (PubMed ID: 32420884)
21. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?
Sommerstein R; Kochen MM; Messerli FH; Gräni C
J Am Heart Assoc; 2020 Apr; 9(7):e016509. PubMed ID: 32233753
[No Abstract] [Full Text] [Related]
22. Noncoding RNAs implication in cardiovascular diseases in the COVID-19 era.
Greco S; Madè A; Gaetano C; Devaux Y; Emanueli C; Martelli F
J Transl Med; 2020 Oct; 18(1):408. PubMed ID: 33129318
[TBL] [Abstract][Full Text] [Related]
23. Clinical characteristics of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV2) patients in Hospital Tengku Ampuan Afzan.
Soh TV; Dzawani M; Noorlina N; Nik F; Norazmi A
Med J Malaysia; 2020 Sep; 75(5):479-484. PubMed ID: 32918413
[TBL] [Abstract][Full Text] [Related]
24. COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity?
Bassendine MF; Bridge SH; McCaughan GW; Gorrell MD
J Diabetes; 2020 Sep; 12(9):649-658. PubMed ID: 32394639
[TBL] [Abstract][Full Text] [Related]
25. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection in South Korea.
Son M; Seo J; Yang S
Hypertension; 2020 Sep; 76(3):742-749. PubMed ID: 32654557
[TBL] [Abstract][Full Text] [Related]
26. Cardiopulmonary Considerations for High School Student-Athletes During the COVID-19 Pandemic: NFHS-AMSSM Guidance Statement.
Drezner JA; Heinz WM; Asif IM; Batten CG; Fields KB; Raukar NP; Valentine VD; Walter KD
Sports Health; 2020; 12(5):459-461. PubMed ID: 32640879
[No Abstract] [Full Text] [Related]
27. Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis.
Ssentongo AE; Ssentongo P; Heilbrunn ES; Lekoubou A; Du P; Liao D; Oh JS; Chinchilli VM
Open Heart; 2020 Nov; 7(2):. PubMed ID: 33154144
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Value of Cardiovascular Biomarkers in COVID-19: A Review.
Aboughdir M; Kirwin T; Abdul Khader A; Wang B
Viruses; 2020 May; 12(5):. PubMed ID: 32403242
[TBL] [Abstract][Full Text] [Related]
29. COVID-19 pandemic and cardiovascular disease: where do we stand?
Chatzis DG; Magounaki KT; Pantazopoulos IN; Johnson EO; Tsioufis KP
Minerva Cardioangiol; 2020 Aug; 68(4):347-358. PubMed ID: 32472990
[TBL] [Abstract][Full Text] [Related]
30. COVID-19 Pandemic: Cardiovascular Complications and Future Implications.
Bandyopadhyay D; Akhtar T; Hajra A; Gupta M; Das A; Chakraborty S; Pal I; Patel N; Amgai B; Ghosh RK; Fonarow GC; Lavie CJ; Naidu SS
Am J Cardiovasc Drugs; 2020 Aug; 20(4):311-324. PubMed ID: 32578167
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic.
Driggin E; Madhavan MV; Bikdeli B; Chuich T; Laracy J; Biondi-Zoccai G; Brown TS; Der Nigoghossian C; Zidar DA; Haythe J; Brodie D; Beckman JA; Kirtane AJ; Stone GW; Krumholz HM; Parikh SA
J Am Coll Cardiol; 2020 May; 75(18):2352-2371. PubMed ID: 32201335
[TBL] [Abstract][Full Text] [Related]
32. Management of Cardiovascular Disease Patients With Confirmed or Suspected COVID-19 in Limited Resource Settings.
Prabhakaran D; Perel P; Roy A; Singh K; Raspail L; Faria-Neto JR; Gidding SS; Ojji D; Hakim F; Newby LK; Stępińska J; Lam CSP; Jobe M; Kraus S; Chuquiure-Valenzuela E; Piñeiro D; Khaw KT; Bahiru E; Banerjee A; Narula J; Pinto FJ; Wood DA; Sliwa K
Glob Heart; 2020 Jul; 15(1):44. PubMed ID: 32923338
[TBL] [Abstract][Full Text] [Related]
33. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease.
Tan W; Aboulhosn J
Int J Cardiol; 2020 Jun; 309():70-77. PubMed ID: 32248966
[TBL] [Abstract][Full Text] [Related]
34. Pharmacotherapeutic considerations for the management of cardiovascular diseases among hospitalized COVID-19 patients.
Kow CS; Thiruchelvam K; Hasan SS
Expert Rev Cardiovasc Ther; 2020 Aug; 18(8):475-485. PubMed ID: 32700573
[TBL] [Abstract][Full Text] [Related]
35. Coronavirus Disease (COVID-19): Implications for Cardiovascular and Socially At-risk Populations.
Dennison Himmelfarb CR; Baptiste D
J Cardiovasc Nurs; 2020; 35(4):318-321. PubMed ID: 32384299
[No Abstract] [Full Text] [Related]
36. COVID-19 in the Cancer Patient.
Yeoh CB; Lee KJ; Rieth EF; Mapes R; Tchoudovskaia AV; Fischer GW; Tollinche LE
Anesth Analg; 2020 Jul; 131(1):16-23. PubMed ID: 32543802
[TBL] [Abstract][Full Text] [Related]
37. Endocrine Conditions and COVID-19.
Shekhar S; Wurth R; Kamilaris CDC; Eisenhofer G; Barrera FJ; Hajdenberg M; Tonleu J; Hall JE; Schiffrin EL; Porter F; Stratakis CA; Hannah-Shmouni F
Horm Metab Res; 2020 Jul; 52(7):471-484. PubMed ID: 32512611
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular disease management during the coronavirus disease 2019 pandemic.
Lee WH; Chen YC; Chen SC; Chen CJ; Hsu PC; Tsai WC; Chu CY; Lee CS; Lin TH; Voon WC; Kuo CH; Su HM
Int J Med Sci; 2020; 17(10):1340-1344. PubMed ID: 32624690
[TBL] [Abstract][Full Text] [Related]
39. Systemic Complications of COVID-19.
Ashraf O; Young M; Malik KJ; Cheema T
Crit Care Nurs Q; 2020; 43(4):390-399. PubMed ID: 32833775
[TBL] [Abstract][Full Text] [Related]
40. Auxiliary role of mesenchymal stem cells as regenerative medicine soldiers to attenuate inflammatory processes of severe acute respiratory infections caused by COVID-19.
Parhizkar Roudsari P; Alavi-Moghadam S; Payab M; Sayahpour FA; Aghayan HR; Goodarzi P; Mohamadi-Jahani F; Larijani B; Arjmand B
Cell Tissue Bank; 2020 Sep; 21(3):405-425. PubMed ID: 32588163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
